| Literature DB >> 35207615 |
Maria Kercheva1,2, Vyacheslav Ryabov1,2,3, Aleksandra Gombozhapova1,2,3, Maria Rebenkova2, Julia Kzhyshkowska4.
Abstract
Changes in the macrophage infiltration of kidneys in rodents under ischemic conditions may affect cardiac macrophages and lead to development of adaptive cardiac remodeling. The aim of our study was to translate experimental findings into clinically relevant applications and assess the features of macrophage infiltration of the kidney and its correlations with changes in macrophage infiltration of the myocardium and with clinical data in patients who experienced a fatal myocardial infarction (MI). We examined fragments of both organs taken from patients (n = 30) who suffered from fatal MI. Macrophage infiltration was assessed by immunohistochemistry. Macrophage infiltration of the kidneys in patients with fatal MI is heterogeneous. The early period of MI was shown to be characterized by the prevalence of CD163+ and CD68+ cells, and in the long-term period by only CD163+ cells. However, only the level of CD206+ cells in the kidneys showed the dynamics representing the late MI period. Its decrease accompanied increase in the numbers of cardiac CD68+, CD163+, CD206+, and stabilin-1+ cells in the infarct area. Kidney CD206+ cells had more correlations with cardiac macrophages than other cells, and the presence of these cells also correlated with impairment of renal function and early death.Entities:
Keywords: CD163; CD206; CD68; cardiac macrophages; cardiac remodeling; inflammation; kidney macrophages; myocardial infarction; stabilin-1
Year: 2022 PMID: 35207615 PMCID: PMC8879726 DOI: 10.3390/jpm12020127
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
Figure 1Changes in macrophage infiltration of kidneys according to the period of myocardial infarction (MI), immunohistochemistry, scale-bar 50 μm. a—early period of MI (n = 17), b—late period of MI (n = 13).
Clinical and anamnestic characteristics of patients (n = 30).
| Parameters | All Patients | Group 1 | Group 2 |
|
|---|---|---|---|---|
| Number of patients, | 30 | 17 (57%) | 13 (43%) | |
| Age, years | 74.8 ± 9.8 | 73 ± 9.3 | 77 ± 10.1 | 0.3 |
| Male sex, | 12 (39%) | 7 (42%) | 5 (38%) | 0.9 |
| STEMI, | 26 (87%) | 16 (94%) | 10 (77%) | 0.2 |
|
| ||||
| Anterior MI, | 10 (33%) | 8 (47%) | 2 (15%) | 0.1 |
| Inferior MI, | 8 (27%) | 3 (18%) | 5 (38%) | 0.3 |
| Anterior-inferior MI, | 12 (40%) | 6 (35%) | 6 (46%) | 0.6 |
|
| ||||
| Diabetes, | 9 (30%) | 4 (23%) | 5 (38%) | 0.5 |
| Arterial hypertension, | 30 (100%) | 17 (100%) | 13 (100%) | 0.4 |
| Obesity, | 10 (33%) | 6 (35%) | 4 (31%) | 0.8 |
| Hypercholesterolemia, | 8 (27%) | 2 (12%) | 6 (46%) | 0.9 |
| Smoking history, | 5 (17%) | 2 (12%) | 3 (23%) | 0.4 |
|
| ||||
| History of MI, | 16 (53%) | 7 (42%) | 9 (69%) | 0.2 |
| CHF, | 15 (50%) | 6 (35%) | 9 (69%) | 0.2 |
| Urolithiasis, | 4 (13%) | 1 (6%) | 3 (23%) | 0.4 |
| CKD at admission, | 10 (33%) | 3 (18%) | 7 (54%) * | 0.05 |
| Creatinine level at admission, μmol/L | 171 ± 85 | 181 ± 93 | 162 ± 78 | 0.7 |
| GFR at admission, mL/min/1.73 m2 | 37 ± 25 | 37 ± 22 | 39 ± 30 | 0.8 |
| CKD KDIGO (G4-G5) | 13 (43%) | 7 (41%) | 6 (46%) | 0.8 |
| Urine volume < 0.5 mL/kg/h for 6 h | 22 (73%) | 12 (70%) | 10 (77%) | 0.2 |
|
| ||||
| LAD, | 16 (53%) | 7 (42%) | 9 (69%) | 0.6 |
| LCA, | 14 (47%) | 6 (35%) | 8 (61%) | 0.9 |
| RCA, | 13 (43%) | 8 (47%) | 5 (38%) | 0.8 |
|
| ||||
| AHF at admission FC > I, | 22 (73%) | 15 (88%) | 7 (54%) * | 0.04 |
| LV aneurysm, | 7 (23%) | 4 (23%) | 3 (23%) | 0.8 |
| Recurrent MI, | 8 (27%) | 1 (6%) | 7 (54%) * | 0.02 |
| Postinfarction angina, | 9 (30%) | 1 (6%) | 7 (54%) * | 0.009 |
|
| ||||
| Cardiogenic shock | 25 (86%) | 12 (70%) | 13 (100%) * | 0.04 |
| Cardiac rupture | 2 (7%) | 2 (28%) | 0 | 0.9 |
| Arrhythmogenic shock (VF) | 2 (7%) | 1 (6%) | 1 (8%) | 0.4 |
Note: *—statistically significant differences between the groups. Abbreviations: AHF—acute heart failure, CAD—coronary artery disease, CHF—chronic heart failure, CKD—chronic kidney disease, FC—functional class, GFR—glomerular filtration rate, MI—myocardial infarction, KDIGO—Kidney Disease: Improving Global Outcomes, LAD—left anterior descending artery, LCA—left circumflex artery, LV—left ventricle, RCA—right coronary artery, STEMI—ST-segment elevation myocardial infarction, VF—ventricular fibrillation.
Dynamics of cardiac and kidney macrophages in patients (n = 30) with fatal MI, depending on the period of MI.
| Parameters (Cells) | All Patients ( | Group 1 ( | Group 2 ( | |
|---|---|---|---|---|
| Kidney CD163+ | 55 (32; 97) | 55 (34; 72) | 58 (32; 97) | 0.8 |
| Cardiac CD163+ (IA) | 460 (62; 846) | 82 (34; 285) | 697 (545; 982) * | 0.001 |
| Cardiac CD163+ (peri-IA) | 82 (49; 135) | 62 (42; 78) | 135 (82; 220) * | 0.005 |
| Cardiac CD163+ (non-IA) | 66 (45; 93) | 70 (45; 87) | 63 (59; 121) | 0.4 |
| Kidney CD206+ | 4 (2; 6) | 6 (5; 8) | 2 (1; 2) * | 0.00004 |
| Cardiac CD206+ (IA) | 31 (12; 106) | 21 (12; 43) | 99 (31; 249) * | 0.02 |
| Cardiac CD206+ (peri-IA) | 24 (12; 41) | 16 (11; 29) | 36 (15; 43) | 0.1 |
| Cardiac CD206+ (non-IA) | 15 (4; 33) | 16 (5; 36) | 14 (4; 16) | 0.2 |
| Kidney CD68+ | 30 (23; 51) | 30 (24; 49) | 35 (23; 51) | 0.9 |
| Cardiac CD68+ (IA) | 106 (56; 376) | 59 (52; 95) | 376 (136; 634) * | 0.00003 |
| Cardiac CD68+ (peri-IA) | 78 (44; 154) | 48 (36; 83) | 154 (85; 232) * | 0.004 |
| Cardiac CD68+ (non-IA) | 67 (38; 115) | 44 (33; 75) | 95 (61; 141) * | 0.03 |
| Kidney stabilin-1+ | 2 (1; 3) | 1 (1; 4) | 2 (1; 2) | 0.8 |
| Cardiac stabilin-1+ (IA) | 1,5 (0; 102) | 0 (0; 1) | 126 (42; 216) * | 0.0001 |
| Cardiac stabilin-1+ (peri-IA) | 1 (0; 13) | 0 (0; 2) | 24 (1; 70) * | 0.01 |
| Cardiac stabilin-1+ (non-IA) | 0 (0; 3) | 0 (0; 0) | 0 (0; 13) | 0.3 |
Note: *—statistically significant difference between the groups. Abbreviations: IA—infarct area, MI—myocardial infarction.
Figure 2Dynamics of cardiac and kidney macrophages in patients (n = 30) with fatal MI. Note: a—infarct area of myocardium, b—peri-infarct area of myocardium, c—non-infarct of myocardium, d—kidney. ∗—statistically significant between the groups.
Features of macrophages diversity in the kidneys in patients (n = 30) with fatal myocardial infarction (MI), depending on the presence of chronic kidney disease (CKD) in history.
| Parameters (Cells) | All Patients ( | CKD+ ( | CKD− ( | |
|---|---|---|---|---|
| Kidney CD163+ | 55 (32; 97) | 61 (34; 97) | 44 (32;88) | 0.3 |
| Kidney CD206+ | 4 (2; 6) | 2 (2; 3) | 5 (2; 6) * | 0.004 |
| Kidney CD68+ | 30 (23; 51) | 35 (17; 51) | 30 (23; 51) | 0.7 |
| Kidney stabilin-1+ | 2 (1; 3) | 1 (1; 2) | 2 (1; 3) | 0.3 |
Note: *—statistically significant differences between the groups.
Figure 3Correlations between kidney and cardiac macrophages in patients with fatal MI.
Summary of multiple linear regression of clinical data and the number of CD206+, CD68+, CD163+, and stabilin-1+ cells in the kidney and early fatal outcome in patients with fatal MI (n = 30).
| Variable | β (Standard Deviation) | T | |
|---|---|---|---|
| History of MI | 0.6 | 3.6 | 0.0002 |
| STEMI | −0.5 | −2.9 | 0.007 |
| Anterior-inferior MI | −0.1 | −0.8 | 0.3 |
| AHF at admission FC > I | 0.4 | 2.5 | 0.02 |
| Kidney CD206+ cells | −0.4 | −3.1 | 0.005 |
| Kidney CD163+ cells | −0.1 | −0.9 | 0.3 |
| Kidney CD68+ cells | 0.04 | 0.2 | 0.7 |
| Kidney stabilin-1+ cells | 0.2 | 1.3 | 0.2 |
Abbreviations: AHF—acute heart failure, FC—functional class, MI—myocardial infarction, STEMI—ST-segment elevation myocardial infarction.